Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb 28;18(8):736-45.
doi: 10.3748/wjg.v18.i8.736.

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Jie-Er Ying  1 , Li-Ming Zhu, Bi-Xia Liu
Affiliations
Review

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Jie-Er Ying et al. World J Gastroenterol. .

Abstract

In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is only about 6 mo. Moreover, phase III trials have shown that adding various cytotoxic and targeted chemotherapeutic agents to gemcitabine has failed to improve overall survival, except in cases in which gemcitabine combined with erlotinib show minimal survival benefit. Several meta-analyses have shown that the combination of gemcitabine with either a platinum analog or capecitabine may lead to clinically relevant survival prolongation, especially for patients with good performance status. Meanwhile, many studies have focused on the pharmacokinetic modulation of gemcitabine by fixed-dose administration, and metabolic or transport enzymes related to the response and toxicity of gemcitabine. Strikingly, a phase III trial in 2010 showed that, in comparison to gemcitabine alone, the FOLFIRINOX regimen in patients with advanced disease and good performance status, produced better median overall survival, median progression-free survival, and objective response rates. This regimen also resulted in greater, albeit manageable toxicity.

Keywords: Biomarkers; Chemotherapy; Metastasis; Palliative therapy; Pancreatic neoplasms.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Surveillance Epidemiology and End Results. U.S. Incidence and Mortality Report. Available from：URL. Cancer Statistics: 1999-; 2007. p. http: //www.seer.cancer.gov/publications/uscs.html (Accessed January 31, 2011).
    1. Loos M, Kleeff J, Friess H, Büchler MW. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci. 2008;1138:169–180. - PubMed
    1. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579. - PubMed
    1. Fung MC, Ishiguro H, Takayama S, Morizane T, Adachi S, Sakata T. Survival benefit of chemotherapy treatment in advanced pancreatic cancer: A meta-analysis. Proc Am Soc Clin Oncol. 2003;22:288 (abstr 1155).

MeSH terms